FI932626A0 - Av en patogenisk aemne haerledande antigenisk polysackarid deriverad oligosackarid - Google Patents

Av en patogenisk aemne haerledande antigenisk polysackarid deriverad oligosackarid

Info

Publication number
FI932626A0
FI932626A0 FI932626A FI932626A FI932626A0 FI 932626 A0 FI932626 A0 FI 932626A0 FI 932626 A FI932626 A FI 932626A FI 932626 A FI932626 A FI 932626A FI 932626 A0 FI932626 A0 FI 932626A0
Authority
FI
Finland
Prior art keywords
derived
oligosaccharides
pathogenic antigenic
antigenic polysaccharides
oligoside
Prior art date
Application number
FI932626A
Other languages
English (en)
Other versions
FI110164B (fi
FI932626A (fi
Inventor
Monique Moreau
Original Assignee
Pasteur Merieux S Rums Et Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux S Rums Et Vacc filed Critical Pasteur Merieux S Rums Et Vacc
Publication of FI932626A0 publication Critical patent/FI932626A0/fi
Publication of FI932626A publication Critical patent/FI932626A/fi
Application granted granted Critical
Publication of FI110164B publication Critical patent/FI110164B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FI932626A 1991-10-10 1993-06-09 Menetelmä oligosakkaridin valmistamiseksi depolymeroimalla antigeeninen polysakkaridi FI110164B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9112478 1991-10-10
FR9112478A FR2682388B1 (fr) 1991-10-10 1991-10-10 Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
FR9200955 1992-10-09
PCT/FR1992/000955 WO1993007178A1 (fr) 1991-10-10 1992-10-09 Oligoside derive d'un polyoside antigenique issu d'un agent pathogene

Publications (3)

Publication Number Publication Date
FI932626A0 true FI932626A0 (fi) 1993-06-09
FI932626A FI932626A (fi) 1993-06-09
FI110164B FI110164B (fi) 2002-12-13

Family

ID=9417772

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932626A FI110164B (fi) 1991-10-10 1993-06-09 Menetelmä oligosakkaridin valmistamiseksi depolymeroimalla antigeeninen polysakkaridi

Country Status (15)

Country Link
US (2) US6045805A (fi)
EP (1) EP0562107B1 (fi)
JP (1) JP3676803B2 (fi)
KR (1) KR100249709B1 (fi)
AT (1) ATE217015T1 (fi)
AU (1) AU661071B2 (fi)
CA (1) CA2098105C (fi)
DE (1) DE69232585T2 (fi)
DK (1) DK0562107T3 (fi)
ES (1) ES2174839T3 (fi)
FI (1) FI110164B (fi)
FR (1) FR2682388B1 (fi)
HU (1) HU219672B (fi)
NO (1) NO306905B1 (fi)
WO (1) WO1993007178A1 (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0658118T3 (da) * 1992-08-31 2002-05-06 Baxter Healthcare Sa Vaccine mod Neisseria meningitidis, gruppe C
PT667787E (pt) * 1992-09-24 2001-10-31 Brigham & Womens Hospital Vacinas de conjugado de polissacarido-proteina de estreptococos do grupo b do tipo ii e tipo v
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5866135A (en) 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5738855A (en) * 1994-10-17 1998-04-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
EP1035137A1 (en) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
DK2332581T3 (en) 2001-01-23 2015-10-05 Sanofi Pasteur Inc Tri- or tetravalent meningococcal polysaccharide-crm197 conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP2284535A1 (en) * 2002-03-11 2011-02-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparins
JP2005526153A (ja) * 2002-03-26 2005-09-02 カイロン ソチエタ ア レスポンサビリタ リミタータ 水中において改善された安定性を持つ修飾糖
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
EP1603950A2 (en) * 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CA2530434A1 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
US20060039899A1 (en) * 2004-08-23 2006-02-23 Winn Robert T Animal nutritional product that increases weight gain and reduces diarrhea morbidity, mortality and severity by stimulation of natural immune response, nutritional support of immune function and supplemental nutricines and probiotics
FR2884830A1 (fr) * 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
FR2899110A1 (fr) 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
MX345967B (es) 2009-10-30 2017-02-28 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
WO2011090948A1 (en) * 2010-01-19 2011-07-28 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
AU2017321863A1 (en) 2016-09-02 2019-04-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US11197921B2 (en) 2017-01-31 2021-12-14 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8200751L (sv) * 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
NL8202527A (nl) * 1982-06-22 1984-01-16 Univ Utrecht Vaccins tegen door bacterien met kapsel-polysacchariden verwekte ziekten en werkwijze voor het bereiden daarvan.
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US5122450A (en) * 1985-10-24 1992-06-16 Research Corporation Limited Biochemical reagent
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
ATE107703T1 (de) * 1986-04-16 1994-07-15 Brigham & Womens Hospital Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
AR243540A1 (es) * 1986-08-05 1993-08-31 Ajorca Sa Procedimiento quimico para la depolimerizacion controlada de polianiones naturales y productos asi obtenidos, excluidos sus usos farmaceuticos.
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines

Also Published As

Publication number Publication date
JPH06506233A (ja) 1994-07-14
AU661071B2 (en) 1995-07-13
NO932102D0 (no) 1993-06-09
CA2098105A1 (fr) 1993-04-10
DK0562107T3 (da) 2002-08-19
CA2098105C (fr) 2003-04-29
DE69232585T2 (de) 2002-12-05
NO932102L (no) 1993-08-05
NO306905B1 (no) 2000-01-10
WO1993007178A1 (fr) 1993-04-15
AU2946992A (en) 1993-05-03
ATE217015T1 (de) 2002-05-15
DE69232585D1 (de) 2002-06-06
US6007818A (en) 1999-12-28
EP0562107B1 (fr) 2002-05-02
ES2174839T3 (es) 2002-11-16
HU219672B (hu) 2001-06-28
KR100249709B1 (ko) 2000-03-15
HU9301682D0 (en) 1993-10-28
US6045805A (en) 2000-04-04
JP3676803B2 (ja) 2005-07-27
FI110164B (fi) 2002-12-13
FR2682388B1 (fr) 1995-06-09
KR930703362A (ko) 1993-11-29
FI932626A (fi) 1993-06-09
EP0562107A1 (fr) 1993-09-29
HUT70298A (en) 1995-09-28
FR2682388A1 (fr) 1993-04-16

Similar Documents

Publication Publication Date Title
FI932626A (fi) Av en patogenisk aemne haerledande antigenisk polysackarid deriverad oligosackarid
FI903865A0 (fi) Ultraäänivarjoaineita, menetelmä niiden valmistamiseksi ja niiden käyttö diagnostisina aineina
NO975387D0 (no) Fremgangsmåte for fremstilling av 3-haloalkyl-1H-pyrazoler
PL289487A1 (en) Method of producing new aminophenol derivatives
ES8105783A1 (es) Un procedimiento para preparar un lipopolisacarido
ATE16496T1 (de) Semi-synthetisches chitinderivat; verfahren zu seiner herstellung.
EP0389235A3 (en) Neutral cure silicone sealants
AU520525B2 (en) Disclosing den., plaque
ZA964749B (en) Method for preparing N,N'disubstituted cyclic ureas.
FI904004A (fi) Anordning foer genomfoerande av avpumpning i synnerhet fraon kanaler, brunnar, tankar eller motsvarande.
DE69011471T2 (de) Lagerfähige, gelformende Einkomponentenfluorosiloxan-Zusammensetzungen mit verbesserter Hitzestabilität.
AU501246B2 (en) 16, 16 disubstituted androstenes
DE69015127T2 (de) Lagerfähige, gelformende Einkomponenten-Fluorsiloxanzusammensetzungen.
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
MX173047B (es) Procedimiento para preparar un compuesto de trifluormetilvinilo
NO904034D0 (no) Fremgangsmaate for fremstilling av 1-etylfenoksatiin-10,10-dioksyd.
ID28174A (id) Turunan 5-imino-13-deoksi antrasiklin, penggunaannya, dan proses pembuatannya
ZA9601216D (en) Novel Antigen.
NO905344L (no) 17,21-alkylderivater av 19-nor-progesteron.
JPS5337361A (en) Dpcm unit
JPS538700A (en) Polymerization of homo-or copolymer of norbornene derivative
TW351725B (en) Novel polyalkylphenol resin and the method for preparing the same
JPS53105583A (en) Polysaccharide sulfate derivative
UA42681C2 (uk) Вакцина проти трихофітії тварин
MX9700585A (es) Derivados de n-alcoxi-amidina y su empleo como agentes pesticidas.

Legal Events

Date Code Title Description
MA Patent expired